In the following video, Motley Fool health care bureau chief Brenton Flynn discusses one of his takeaways from yesterday at the JPMorgan conference: the presentation from Abbott Labs (ABT 1.21%). This is the first time we've heard from the company since it spun off its branded pharmaceuticals business into a new company, AbbVie (ABBV 0.56%), at the beginning of the year. Here, Flynn spells out for us Abbott's strategy going forward with two words.
Editor's note: The video above failed to address a key difference between the Boston Scientific and Abbott Labs stent technologies. Abbott's Absorb stent fully absorbs into the body, while Boston Scientific's Synergy stent retains a metallic implant after a polymer coating absorbs into the body. The Fool regrets the error.
